EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies

Oleg Demin iD, Ying Ou iD, Galina Kolesova, Dmitry Shchelokov, Alexander Stepanov iD, Veronika Musatova, Sri Sahasranaman, Yating Zhao, Xiangyu Liu iD, Zhiyu Tang, William D Hanley

CPT: Pharmacometrics & Systems Pharmacology · 2025-04 · 14 (4) · 706-717

DOI: 10.1002/psp4.13307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 12.02.2025. Verfasst von Oleg Demin und 10 weiteren Autor:innen. Beteiligte Einrichtung: InSysBio CY, Limassol, Cyprus. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors, Models, Biological, Lymphoma, B-Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BeiGene.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The effectiveness of Bruton tyrosine kinase (BTK) inhibitors is influenced by the level of BTK occupancy in target tissues. In randomized phase 3 studies, progression‐free survival (PFS) with zanubrutinib was superior to ibrutinib, whereas acalabrutinib was noninferior to ibrutinib in previously treated chronic lymphocytic leukemia. To establish a link between numerical differences in BTK occupancy and differentiated efficacy profiles among three covalent BTK inhibitors, quantitative systems pharmacology (QSP) modeling was employed. The model was developed to describe available clinical BTK occupancy data in patients with B‐cell malignancies. Simulations of BTK occupancy were conducted for various clinical scenarios (e.g., dose interruption) and for bone marrow (BM), for which routine measurements are difficult. This model describes pharmacokinetics of BTK inhibitors; intracellular concentration of BTK inhibitors in peripheral blood mononuclear cells (PBMCs), BM, and lymph nodes (LNs); binding of BTK inhibitors with BTK; and BTK turnover rate. The model was validated using available clinical BTK occupancy data. Consistent with observed clinical data, the model predicted that zanubrutinib 160 mg twice daily resulted in higher median trough BTK occupancy in PBMCs, LNs, and BM compared with ibrutinib and acalabrutinib. Although the BTK occupancy differences at trough were relatively small between the BTK inhibitors, the differences were more pronounced after dose interruption. The current work underscores the importance of maintaining high BTK occupancy at steady‐state trough and during treatment interruption to ensure maximal efficacy and provides an example of combining in vitro and clinical data to model receptor occupancy in tissues where measurements are challenging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsModels, BiologicalLymphoma, B-CellLeukemia, Lymphocytic, Chronic, B-CellAntineoplastic AgentsHumansPiperidinesAdeninePyrazolesPyrimidinesPyrazinesBenzamidesTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

BTKquantitative systems pharmacology modelsreceptor occupancy

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsPiperidinesAdenineibrutinibacalabrutinibBTK protein, humanzanubrutinibPyrazolesPyrimidines

Autor:innen und Institutionen

  • InSysBio CY, Limassol, Cyprus.
  • Clinical Pharmacology, BeiGene USA Inc., San Mateo, California, USA.
  • Prelude Therapeutics, Wilmington, Delaware, USA.

ORCID-Profile: Oleg Demin, Ying Ou, Alexander Stepanov, Xiangyu Liu

Förderung

  • BeiGene

Zitieren

APA

Demin, O., Ou, Y., Kolesova, G., Shchelokov, D., Stepanov, A., Musatova, V., Sahasranaman, S., Zhao, Y., Liu, X., Tang, Z., & Hanley, W. D. (2025). Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies. CPT: Pharmacometrics & Systems Pharmacology, 14(4), 706-717. https://doi.org/10.1002/psp4.13307

Vancouver

Demin O, Ou Y, Kolesova G, Shchelokov D, Stepanov A, Musatova V, et al. Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies. CPT: Pharmacometrics & Systems Pharmacology. 2025;14(4):706-717. doi:10.1002/psp4.13307

BibTeX
@article{Demin2025,
  author = {Demin, Oleg and Ou, Ying and Kolesova, Galina and Shchelokov, Dmitry and Stepanov, Alexander and Musatova, Veronika and Sahasranaman, Sri and Zhao, Yating and Liu, Xiangyu and Tang, Zhiyu and Hanley, William D},
  title = {Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  volume = {14},
  number = {4},
  pages = {706--717},
  doi = {10.1002/psp4.13307}
}
Kostenlos starten →